{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014067","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.869881+00:00","generated_at":"2026-06-04T00:47:22.193490+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NanoVibronix Q4 2023 revenue $1.2M record; CMS reimbursement still not approved","bullets":["Q4 2023 revenue of $1.2M (record quarter); loss from operations of $702K.","Cash of $3.3M, inventory $2.7M; raised $4.2M net in Q3 2023.","CMS reimbursement for PainShield still not approved; efforts continue.","University of Michigan to initiate UroShield RCT (pilot 30, full study 300+).","Selected engineering partner for next-gen product development expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014067","json":"https://secwatch.observer/filing/0001493152-24-014067.json","markdown":"https://secwatch.observer/filing/0001493152-24-014067.md","text":"https://secwatch.observer/filing/0001493152-24-014067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224014067/0001493152-24-014067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224014067/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:47:22.193490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}